[go: up one dir, main page]

WO1992002819A3 - Assay for ulcerative colitis and primary sclerosing cholangitis - Google Patents

Assay for ulcerative colitis and primary sclerosing cholangitis Download PDF

Info

Publication number
WO1992002819A3
WO1992002819A3 PCT/US1991/005276 US9105276W WO9202819A3 WO 1992002819 A3 WO1992002819 A3 WO 1992002819A3 US 9105276 W US9105276 W US 9105276W WO 9202819 A3 WO9202819 A3 WO 9202819A3
Authority
WO
WIPO (PCT)
Prior art keywords
ulcerative colitis
sclerosing cholangitis
primary sclerosing
assay
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1991/005276
Other languages
French (fr)
Other versions
WO1992002819A2 (en
Inventor
Stephan R Targan
Fergus L J Shanahan
Carol J Landers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Publication of WO1992002819A2 publication Critical patent/WO1992002819A2/en
Publication of WO1992002819A3 publication Critical patent/WO1992002819A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/554—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being a biological cell or cell fragment, e.g. bacteria, yeast cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Physiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention provides a method for detecting the presence of diseases including ulcerative colitis or primary sclerosing cholangitis in a patient. The method consists of contacting a body sample of the patient with immobilized neutrophils so as to allow the antineutrophilic cytoplasmic antibodies to bind to the neutrophils. Further, the method provides detecting bound anti-neutrophilic cytoplasmic antibodies, the presence of the antibodies indicative of the disease state.
PCT/US1991/005276 1990-08-10 1991-07-25 Assay for ulcerative colitis and primary sclerosing cholangitis Ceased WO1992002819A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56605190A 1990-08-10 1990-08-10
US566,051 1990-08-10

Publications (2)

Publication Number Publication Date
WO1992002819A2 WO1992002819A2 (en) 1992-02-20
WO1992002819A3 true WO1992002819A3 (en) 1992-03-19

Family

ID=24261265

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1991/005276 Ceased WO1992002819A2 (en) 1990-08-10 1991-07-25 Assay for ulcerative colitis and primary sclerosing cholangitis

Country Status (1)

Country Link
WO (1) WO1992002819A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9211176D0 (en) * 1992-05-27 1992-07-08 Central Blood Lab Authority Assay
US5830675A (en) * 1993-03-10 1998-11-03 Cedars-Sinai Medical Center Methods for selectively detecting perinuclear anti-neutrophil cytoplasmic antibody of ulcerative colitis, primary sclerosing cholangitis, or type 1 autoimmune hepatitis
DK0615129T3 (en) * 1993-03-10 2000-08-07 Cedars Sinai Medical Center Methods for selective detection of perinuclear anti-neutrophil cytoplasmic antibody from ulcerative colitis or
US5681699A (en) * 1994-02-11 1997-10-28 Cedars-Sinai Medical Center Methods of diagnosing ulcerative colitis and Crohn's disease
US6884590B1 (en) 1994-02-11 2005-04-26 Cedars-Sinai Medical Center Methods of screening for ulcerative colitis and crohn's disease
US5738847A (en) * 1994-09-19 1998-04-14 The Regents Of The University Of California Anti-VH3-15 reagents and methods for their use
US5691151A (en) * 1994-10-07 1997-11-25 Regents Of University Of California Methods of screening for ulcerative colitis and crohn's disease by detecting VH3-15 autoantibody and panca
RU2141661C1 (en) * 1998-11-18 1999-11-20 Московский медицинский стоматологический институт Method of treatment of peptic ulcer
WO2010062960A2 (en) 2008-11-26 2010-06-03 Cedars-Sinai Medical Center METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE
US9580752B2 (en) 2008-12-24 2017-02-28 Cedars-Sinai Medical Center Methods of predicting medically refractive ulcerative colitis (MR-UC) requiring colectomy
WO2014160883A1 (en) 2013-03-27 2014-10-02 Cedars-Sinai Medical Center Treating fibrosis and inflammation by inhibiting tl1a
US10316083B2 (en) 2013-07-19 2019-06-11 Cedars-Sinai Medical Center Signature of TL1A (TNFSF15) signaling pathway
EP3121289A1 (en) 2015-07-22 2017-01-25 Humanitas Mirasole S.p.A. Micrornas as biomarkers of bile duct diseases
KR102464372B1 (en) 2016-03-17 2022-11-04 세다르스-신나이 메디칼 센터 Methods of diagnosing inflammatory bowel disease through rnaset2

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CLINICAL AND EXPERIMENTAL IMMUNOLOGY vol. 76, 1989, OXFORD UK pages 30 - 33; J.A. SNOOK ET AL.: 'Anti-neutrophil nuclear antibody in ulcerative colitis, Crohns disease and primary sclerosing cholangitis.' See whole article. *
GASTROENTEROLOGY vol. 100, no. 6, 1 September 1991, WASHINGTON DC USA pages 1590 - 1599; R.H. DUERR ET AL.: 'Anti-neutrophil cytoplasmic antibodies in ulcerative colitis.' See whole article., *
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY vol. 86, no. 2, 1 August 1990, PHILADELPHIA PA USA pages 202 - 210; A. SAXON ET AL.: 'A distinct subset of antineutrophil cytoplasmic antibodies is assiciated with inflammatory bowel disease.' See whole article. *

Also Published As

Publication number Publication date
WO1992002819A2 (en) 1992-02-20

Similar Documents

Publication Publication Date Title
WO1992002819A3 (en) Assay for ulcerative colitis and primary sclerosing cholangitis
AU5799898A (en) Method for improving the recovery of troponin i and t
CA2000545A1 (en) Process and reagent for the determination of a specifically bindable substance
EE05465B1 (en) A method for detecting allergen-associated immunoglobulin in a sample, a method for in vitro diagnosis of a patient's allergies, a microarray chip and a kit
WO1998018826A3 (en) Anti-CCR5 antibodies and methods of use therefor
WO2000005265A3 (en) Anti-crr2 antibodies and methods of use therefor
AU1198895A (en) Sensor device for sandwich assay
ES2131690T3 (en) DEVICE FOR THE DOSAGE OF HAPTENES AND THEIR USE.
FI2645106T4 (en) Methods for evaluating an immune response to a therapeutic agent
SE8701905D0 (en) A METHOD AND A KIT FOR THE DIAGNOSIS OF IGA NEPHROPATHY
AU7336400A (en) Diagnostic assay for type 2 heparin-induced thrombocytopenia
WO2003046140A3 (en) Immunoassay and kit for an early and simulataneous detection of biochemical markers in a patient's sample
FI944225L (en) Diagnostic reagents for the detection of EBV antibodies
CA2366514A1 (en) Diagnostic and therapeutic use of antibodies against the urokinase receptor
CA2417161A1 (en) Method for immuno-detection of epitopes
GB2307041B (en) Sheets,kits and methods for detecting antigens or antibodies
CA2043862A1 (en) Assay for cobalamins
WO2001004633A3 (en) Preparation of spheres for diagnostic tests
EP0387027A3 (en) Endometriosis diagnosis methods and reagents
WO2000050455A3 (en) Antigen to systemic lupus erythematosis and diagnostic assay
KR920703844A (en) Methods for measuring T-cell surface antigens in humans
IL108811A0 (en) Immunoassay reagents, kits and methods
WO1999001085A3 (en) Autoimmune inner ear disease antigen and diagnostic assay
EP0782863A4 (en) Antibody reagent for detecting dissecting aortic aneurysm and use thereof
EP0313005A3 (en) Method for detecting carcinomatous and precarcinomatous colo-rectal disease

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE